Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients

Patrizia Vici, Laura Pizzuti, Luigi Di Lauro, Laura Conti, Chiara Mandoj, Anna Antenucci, Giovanna Digiesi, Domenico Sergi, Antonella Amodio, Paolo Marchetti, Francesca Sperati, Mario Valle, Alfredo Garofalo, Enrico Vizza, Giacomo Corrado, C. Vincenzoni, Federica Tomao, Ramy Kayal, Annalise Marsella, Mariantonia CarosiBarbara Antoniani, Antonio Giordano, Marcello Maugeri-Saccà, Maddalena Barba

Research output: Contribution to journalArticlepeer-review


Background: Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. Results: For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.

Original languageEnglish
Pages (from-to)516-522
Number of pages7
JournalJournal of Cancer
Issue number5
Publication statusPublished - 2016


  • Body mass index
  • Epithelial ovarian cancer
  • Fasting glucose
  • FIGO stage
  • Tumour grade

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Metabolic determinants and anthropometric indicators impact clinical-pathological features in epithelial ovarian cancer patients'. Together they form a unique fingerprint.

Cite this